


# Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

November 2016



# Global Biosimilar Market

## Scope of the Report

The report entitled "Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)", provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biosimilar market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies of the companies.

# Global Biosimilar Market

## Company Coverage

Sandoz

Amgen

Celltrion

Pfizer

# Global Biosimilar Market

## Executive Summary

Biologics are drugs made by a living cell, typically an engineered bacterium or yeast. It refers to a wide range of medicinal products such as vaccines, blood or blood components, somatic cells and gene therapy etc. which are used as therapeutics to treat diseases. Biologics are made through biological processes and are mostly injectable in nature because these are large molecule substances which degraded if taken orally. Biologics are classified as First-Generation Biologics and Second-Generation Biologics. When the patent surrounding a biologic's formula is no longer protected multiple companies can release a drug with the same chemical recipe, driving the cost down. That new biologic drug is a biosimilar. There is no clinical difference between biological products and the reference products and are also known as "follow-on-biologics".


Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set to expire in December 2016, incentivizes a large number of companies to enter into biosimilar market.

The biosimilar market is in its early stages, but is expected to grow in the next five years. The global biosimilar market is supported by various growth drivers such as growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic disease among aging population and positive outcomes in ongoing clinical trials etc. Yet the market faces some challenges, such as restrict entry of new players, the complexity of manufacturing biosimilars and clinical limitations including patient recruitment obstacles.


# Global Biosimilar market

The global biosimilar market was valued at US\$.....in 2015 and is estimated to reach US\$.....in 2016. Growth in the market was primarily driven by growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic diseases among aging population and positive outcomes in ongoing clinical trial

**Global Pharmaceutical Market by Value;  
2015-2020E (US\$ Billion)**




**Global Biosimilar Market; 2015-2020E  
(US\$ Billion)**



In the forecasted period, market is expected to grow on the back of emergence of new market participants, inclusion of drug delivery device, uberization of healthcare industry and increasing use of single-use technology.

# Global Biosimilar Market

Global Biologics Market; 2010-2015 (US\$ Billion)



Global Biologics Market Share by Products; 2015

